This ASX stock is going parabolic, and I think it's still a buy

Shares in 4DMedical Ltd (ASX: 4DX) have been nothing short of extraordinary in 2025. What started the year as a relatively unknown small-cap healthcare name has turned into one of the ASX's standout momentum stories.

At Wednesday's close, shares in the respiratory imaging technology company finished at $2.83, down 5% amid broader market volatility.

Even after that pullback, the stock is still up close to 500% in 2025.

It's easy to assume most of the upside is already gone. But a closer look suggests there may still be more left in this growth stock.

What does 4DMedical actually do?

4DMedical operates in medical imaging, using software to turn standard CT scans into highly detailed, four-dimensional images of lung function. Its core XV Technology gives clinicians a clearer picture of how a patient's lungs are actually working, revealing issues traditional imaging can miss, especially in chronic and complex respiratory conditions.

That matters because many lung diseases are hard to diagnose and monitor using existing tools. Hospitals and clinicians are always looking for better ways to assess, track, and treat conditions like COPD, asthma, and post-COVID complications. 4DMedical's software is designed specifically to help solve that problem.

Why has the share price exploded?

The recent rally has not been driven by hype alone. Over the past few months, 4DMedical has delivered a steady stream of positive news.

Key regulatory approvals in major overseas markets, including Canada, have significantly expanded its addressable customer base. At the same time, the company has announced new commercial agreements and partnerships that validate its technology in real-world clinical settings.

Importantly, these updates have shifted investor perception. 4DMedical is no longer seen purely as an early-stage biotech with promise, but as a business starting to turn its technology into revenue.

Revenue is becoming more visible

Until recently, 4DMedical shares were largely priced on future potential. However, that's starting to change as revenue becomes more visible.

Software sales are growing, more hospitals are using the product, and interest from overseas customers is increasing. The company isn't profitable yet, but as a software business, more users should improve the numbers over time.

This has prompted the market to reassess the stock.

What could go wrong and what could go right?

None of this comes without risk. The share price has already moved sharply, volatility is likely to remain high, and expectations are rising. Slower execution or weaker adoption would likely impact the stock.

Even so, the longer-term opportunity is still there. If 4DMedical continues to expand into new markets and sees its technology adopted more widely in clinical settings, today's valuation could still have room to grow.

The bottom line

4DMedical has been one of the ASX's stronger performers in 2025.

For investors who understand the risks and are comfortable with volatility, this parabolic ASX stock still looks like one worth keeping firmly on the watchlist, even after its huge run.

The post This ASX stock is going parabolic, and I think it's still a buy appeared first on The Motley Fool Australia.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2025